|
Avaliação Valneva SE (Valn) DCF
FR | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Valneva SE (VALN) Bundle
Obtenha informações sobre sua análise de avaliação Valneva SE (VALN) com nossa sofisticada calculadora DCF! Equipado com dados reais de Valneva SE (VALN), este modelo do Excel permite ajustar as previsões e suposições para determinar com precisão o valor intrínseco de Valneva SE (VALN).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 131.0 | 114.5 | 361.2 | 375.0 | 159.5 | 173.0 | 187.6 | 203.4 | 220.6 | 239.2 |
| Revenue Growth, % | 0 | -12.58 | 215.52 | 3.8 | -57.46 | 8.44 | 8.44 | 8.44 | 8.44 | 8.44 |
| EBITDA | 10.1 | -47.9 | -48.6 | -103.2 | -59.9 | -39.0 | -42.3 | -45.8 | -49.7 | -53.9 |
| EBITDA, % | 7.7 | -41.8 | -13.46 | -27.51 | -37.55 | -22.53 | -22.53 | -22.53 | -22.53 | -22.53 |
| Depreciation | 8.9 | 10.2 | 14.8 | 21.8 | 18.2 | 12.8 | 13.9 | 15.1 | 16.3 | 17.7 |
| Depreciation, % | 6.76 | 8.88 | 4.1 | 5.82 | 11.44 | 7.4 | 7.4 | 7.4 | 7.4 | 7.4 |
| EBIT | 1.2 | -58.0 | -63.5 | -125.0 | -78.2 | -51.8 | -56.1 | -60.9 | -66.0 | -71.6 |
| EBIT, % | 0.93505 | -50.68 | -17.57 | -33.33 | -48.99 | -29.93 | -29.93 | -29.93 | -29.93 | -29.93 |
| Total Cash | 66.9 | 212.1 | 359.8 | 300.4 | 130.8 | 142.8 | 154.9 | 167.9 | 182.1 | 197.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 24.9 | 20.0 | 45.7 | 24.8 | 43.2 | 28.7 | 31.1 | 33.7 | 36.5 | 39.6 |
| Account Receivables, % | 19.04 | 17.43 | 12.64 | 6.62 | 27.09 | 16.57 | 16.57 | 16.57 | 16.57 | 16.57 |
| Inventories | 26.7 | 28.0 | 128.8 | 36.4 | 46.1 | 41.2 | 44.7 | 48.5 | 52.6 | 57.0 |
| Inventories, % | 20.42 | 24.41 | 35.65 | 9.72 | 28.93 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 |
| Accounts Payable | 9.2 | 25.8 | 16.6 | 15.1 | 18.2 | 17.2 | 18.6 | 20.2 | 21.9 | 23.8 |
| Accounts Payable, % | 7.03 | 22.57 | 4.61 | 4.01 | 11.43 | 9.93 | 9.93 | 9.93 | 9.93 | 9.93 |
| Capital Expenditure | -11.3 | -20.2 | -96.7 | -30.4 | -14.9 | -24.4 | -26.4 | -28.7 | -31.1 | -33.7 |
| Capital Expenditure, % | -8.62 | -17.65 | -26.77 | -8.12 | -9.31 | -14.09 | -14.09 | -14.09 | -14.09 | -14.09 |
| Tax Rate, % | -2.84 | -2.84 | -2.84 | -2.84 | -2.84 | -2.84 | -2.84 | -2.84 | -2.84 | -2.84 |
| EBITAT | 2.5 | -57.2 | -66.6 | -123.7 | -80.4 | -51.5 | -55.9 | -60.6 | -65.7 | -71.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -42.5 | -46.8 | -284.2 | -20.6 | -101.9 | -44.7 | -72.9 | -79.0 | -85.7 | -92.9 |
| WACC, % | 9.62 | 9.59 | 9.62 | 9.59 | 9.62 | 9.6 | 9.6 | 9.6 | 9.6 | 9.6 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -279.5 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -95 | |||||||||
| Terminal Value | -1,246 | |||||||||
| Present Terminal Value | -788 | |||||||||
| Enterprise Value | -1,067 | |||||||||
| Net Debt | 86 | |||||||||
| Equity Value | -1,153 | |||||||||
| Diluted Shares Outstanding, MM | 139 | |||||||||
| Equity Value Per Share | -8.32 |
What You Will Get
- Real VALN Financials: Access to historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Valneva SE's future performance.
- User-Friendly Design: Crafted for industry professionals while remaining easy to navigate for newcomers.
Key Features
- Real-Life VALN Data: Pre-filled with Valneva SE’s historical financials and future projections.
- Fully Customizable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatically updates Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Generate multiple forecast scenarios to evaluate different valuation outcomes.
- User-Friendly Design: Intuitive, organized, and suitable for both professionals and beginners.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Valneva SE (VALN) data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Valneva SE’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Valneva SE (VALN)?
- Designed for Experts: A sophisticated tool utilized by researchers, financial analysts, and investors.
- Comprehensive Data: Valneva’s historical and projected financials are preloaded for precise analysis.
- Flexible Scenario Analysis: Easily test various forecasts and assumptions to evaluate outcomes.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential financial metrics.
- User-Friendly: Step-by-step guidance ensures a smooth and straightforward experience.
Who Should Use This Product?
- Investors: Assess Valneva SE’s (VALN) valuation prior to making investment decisions.
- CFOs and Financial Analysts: Enhance valuation methodologies and evaluate financial forecasts.
- Startup Founders: Discover how biopharmaceutical companies like Valneva SE are appraised.
- Consultants: Provide expert valuation analyses and reports for clients focused on biotech.
- Students and Educators: Utilize current data to learn and teach valuation concepts in the biotech sector.
What the Template Contains
- Historical Data: Includes Valneva SE’s past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Valneva SE’s intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Valneva SE’s financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.